Tatiana Valerievna Klypa

Tatiana Valerievna Klypa

Auto-generated profile, based on publicly available information

Tatiana Valerievna Klypa

Federal Research Clinical Center of the Federal Medical-Biological Agency

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2020 in Journal of Clinical Practice
Verified
Journal Article
Open access
PDF file
TKTatiana V. Klypa
Tatiana V. Klypa
MBMikhail V. Bychinin
Mikhail V. Bychinin
Irina MandelIrina Mandel
Irina Mandel
SASergey A. Andreichenko
Sergey A. Andreichenko
AMAndrey I. Minets
Andrey I. Minets
МИМинец Андрей Иванович
Минец Андрей Иванович
Background. Providing an efficient care to the patients of the most severely affected category ICU patients has become one of the serious problems appearing in the COVID-19 pandemics. A typical patients clinical portrait in ICUs of COVID centers is very similar in different countries, however, the key to improve the treatment results for critically ill patients has not yet been found. Currently, 160 patients have been treated in the ICU of the FRCC of the FMBA of Russia. To May 16, 2020, the lethality in the ICU was 48.9% by the closed cases, the lethality among the patients on ventilation was 57.9%. The aim of the study is to identify predictors of the severe pneumonia caused by the SARS-CoV-2 virus, and to describe the clinical characteristics of patients admitted to an intensive care unit of the COVID-center of the Federal Research Clinical Center of FMBA of Russia. Methods. In this report, we describe the clinical, laboratory and instrumental data of 70 patients admitted to the ICU, and discuss the found predictors of the severe COVID-19 pneumonia course. Results. The following factors have been determined which contribute to the development of the severe course of the disease and to the risk of the unfavorable outcome: male gender, age older than 70.5 years, initial lymphocytopenia of lower than 0.98109/l, neutrophil to lymphocyte ratio of higher than 7.75, D-dimer level of higher than 0.85 g/ml, IL-6 of higher than 184.7 pg/ml, procalcitonin of higher than 0.22 ng/ml, hyperglycemia of higher than 9 mmol/l, signs of myocardial damage (high-sensitive troponin Т of higher than 22 pg/ml, echocardiography data), signs of the presence of a secondary bacterial infection and a severe vitamin D deficiency (lower than 9.9 ng/ml). The pathophysiological basics for the contribution of each factor to the severe course of the disease are provided. Conclusions. Clinical features of the patients change in course of pandemia. These influenced by changes in treatment approaches and new discoveries in disease pathophysiology. Above mentioned predictors of severe course of disease is partly modifiable and we are able to influence them and perhaps achieve better results in treatment of severe patients with COVID-19

1 August 2021 in The Journal of Nutrition
Verified
Journal Article
Closed access
MBMikhail V Bychinin
Mikhail V Bychinin
TKTatiana V Klypa
Tatiana V Klypa
Irina MandelIrina Mandel
Irina Mandel
SASergey A Andreichenko
Sergey A Andreichenko
VBVladimir P. Baklaushev
Vladimir P. Baklaushev
ATAleksandr V Troitsky
Aleksandr V Troitsky
Vitamin D deficiency has been associated with an increased risk of respiratory infections. The study aimed to evaluate the serum 25-hydroxyvitamin D [25(OH)D] concentration in patients admitted to the intensive care unit (ICU) as a predictor of coronavirus disease 2019 (COVID-19) mortality. A single-center retrospective observational study was conducted. Forty adult patients (50% men) with confirmed COVID-19 who were admitted to the ICU were enrolled. The primary endpoint was mortality at day 60. Serum 25(OH)D concentration was measured on the day of admission to the ICU. We used the Mann-Whitney test, Fisher's exact test, Kaplan-Meier analysis, and receiver operator characteristic (ROC) analysis to assess serum 25(OH)D concentration as a predictor of COVID-19 mortality. All 40 patients had a low median (IQR) serum 25(OH)D concentration at admission [12 (9-15) ng/mL]. The median (IQR) serum 25(OH)D concentration was greater in survivors [13.3 (10.0-17.1) ng/mL, n = 22] than in nonsurvivors [9.6 (7.9-14.2) ng/mL; n = 18], P = 0.044. The area under the ROC curve was 0.69 (95% CI: 0.52, 0.86; P = 0.044). The 60-d mortality rate of those with serum 25(OH)D concentrations ≤9.9 ng/mL (n = 14, 71%) tended to be greater than that of those with concentrations >9.9 ng/mL (n = 26, 31%) (P = 0.065), and they had a 5.6-fold higher risk of death (OR: 5.63; 95% CI: 1.35, 23.45; P = 0.018). The ICU patients had a low serum 25(OH)D concentration. Serum 25(OH)D concentrations ≤9.9 ng/mL on admission can be used to predict in-hospital mortality in patients with COVID-19.This trial was registered at clinicaltrials.gov as NCT04450017.

17 July 2020 in Journal of Clinical Practice
Verified
Journal Article
Open access
VBVladimir P. Baklaushev
Vladimir P. Baklaushev
AAA. V. Averyanov
A. V. Averyanov
ASA. G. Sotnikova
A. G. Sotnikova
APAnastasia S. Perkina
Anastasia S. Perkina
Alexander V. IvanovAlexander V. Ivanov
Alexander V. Ivanov
ATAlexander V. Troitskiy
Alexander V. Troitskiy
Introduction. The lack of effective aetiotropic therapy of COVID-19 prompted researchers around the world searching for various methods of SARS-CoV-2 elimination, including convalescent plasma. The aim of this work was to study the safety and efficacy of severe COVID-19 treatment with convalescence plasma containing specific antibodies to the receptor binding domain (RBD) of SARS-CoV-2 S protein in a titer of at least 1: 1000. Methods. A single-center, randomized, prospective, clinical study performed at the FRCC FMBA of Russia with the participation of 85 patients who were stratified in two groups. The first group contains 20 critically ill patients who are on mechanical ventilation; Results. The use of plasma of convalescents in patients with severe COVID-19 with mechanical ventilation does not affect the disease outcome in these patients. Mortality rate in this group was 60%, which corresponds to the average mortality of patients on mechanical ventilation in our hospital. In the second group clinical improvement was detected in 75% and 51%, for convalescent and normal plasma respectively. Of the 46 people who received convalescent plasma, three patients (6.5%) were transferred to mechanical ventilation, two of whom died. In the group receiving non-immune plasma, the need for mechanical ventilation also arose in three patients (15%), of which two died. The hospital mortality in the group of convalescent plasma was 4.3%, which is significantly lower than the average COVID-19 hospital mortality in our Center (6.73%) and more than two times lower than the hospital mortality in the control group (n = 150), matched by age and by the disease severity. Conclusions. Thus, we demonstrated relative safety of convalescent plasma transfusion and the effectiveness of such therapy for COVID-19 at least in terms of the survival of patients with severe respiratory failure without mechanical ventilation. In the absence of bioengineered neutralizing antibodies and effective aetiotropic therapy, the use of hyperimmune convalescent plasma is the simplest and most effective method of specific etiopathogenetic therapy using forms of COVID-19.

3 August 2024 in Head and Neck Tumors (HNT)
Verified
Journal Article
Open access
PDF file
AKA. E. Karelov
A. E. Karelov
AOA. M. Ovezov
A. M. Ovezov
IZI. B. Zabolotskikh
I. B. Zabolotskikh
VKV. E. Khoronenko
V. E. Khoronenko
GAG. R. Abuzarova
G. R. Abuzarova
ЮКЮ. Н. Краевская
Ю. Н. Краевская
Introduction. The role of peptides in antinociceptive system regulation has became a subject of interest for scientists worldwide. The first registered peptide analgesic tyrosyl-D-arginyl-phenylalanyl-glycinamide acetate which currently can be used in clinical practice was developed in Russia under the name Taphalgin® (PharmFirma “Sotex”, Russia). The effectiveness and safety of this pharmaceutical in postoperative pain management was evaluated in the all-Russia multicenter prospective observation program NICITA (Non-interventional Clinical Trial of Taphalgin ®).Aim. To analyze the effectiveness and safety of Taphalgin® in postoperative pain management in various surgical fields.Materials and methods. The observational program NICITA included 887 patients including patients with malignant tumors of various locations from 15 study centers in different Russian cities. All patients underwent surgical interventions in various anatomical areas under general, regional and combination anesthesia. The principal scheme of postoperative pain management was based on the multimodal approach which included peptide opioid agonist alongside acetaminophen, cyclooxygenase inhibitors in combination with regional anesthesia or without it. The study also included patients who underwent small-volume surgeries, and pain was managed through Taphalgin® monotherapy with subsequent switch to cyclooxygenase inhibitors. The primary endpoint of the NICITA observational program was response to therapy after the first Taphalgin® administration. Decreased pain syndrome per the numerical rating scale 15–60 min after subcutaneous injection and maintenance of analgesic effect 3 h later were considered treatment response. The secondary endpoints included mean time to analgesia start after administration of the 1st single drug dose (in min), duration of effect, types and frequency of adverse reactions including serious in the central nervous system, pulmonary system, gastrointestinal tract developed during the observational program, as well as patient and research physician satisfaction with pain management. To evaluate the significance of pain intensity change at rest and in motion in time, analysis of variance with repeat measurements was used; for pairwise comparison of two time periods, Student’s t-test for dependent samples was used. The differences were considered significant at p = 0.05.Results. Statistically significant decrease in pain intensity in the total patient group was observed 15 minutes after Taphalgin® administration; it reached its minimum 40 min after the injection (р 0.05). The percentage of patients responding to analgesic therapy with Taphalgin® was 96.5 %. During administration of the drug, insignificant decrease (10–15 mmHg) in arterial blood pressure (1.7 % of cases) and vertigo (1 % of cases) were observed. In some patients, several adverse reactions were observed. Satisfaction with analgesic effect of Taphalgin® was relatively high both in patients and research physicians.Conclusion. Taphalgin® has pronounced analgesic effect and is effective for pain management after surgical interventions of various volumes and injury level. The use of this drug is associated with low rate of adverse reactions and absence of pulmonary depression characterizing opioid agonists. Therefore, Taphalgin® can be recommended for clinical use for postoperative pain management after various types of surgical interventions.

23 April 2023 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
AGA.A. Gukalov
A.A. Gukalov
TKT.V. Klypa
T.V. Klypa
Irina MandelIrina Mandel
Irina Mandel
AMA.I. Minets
A.I. Minets
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить эффективность и безопасность применения фиксированной комбинации диклофенака и орфенадрина для обезболивания в раннем послеоперационном периоде у ортопедических больных после протезирования тазобедренного сустава. МАТЕРИАЛ И МЕТОДЫ В исследование включили 65 пациентов с эндопротезированием тазобедренного сустава в условиях спинальной анестезии бупивакаином. Пациенты были разделены на две группы: основную и контрольную (39 и 26 пациентов соответственно). В основной группе пациентам проводили инфузию неодолпассе (орфенадрин 30 мг + диклофенак 75 мг) после окончания операции и инфузию морфина в режиме пациентоконтролируемой аналгезии (ПКА). В контрольной группе проводили монотерапию морфином в режиме ПКА. Сравнивали интенсивность болевого синдрома по визуальной аналоговой шкале (ВАШ) от 0 до 100 мм, количество введенного морфина, количество запросов болюсов, оценивали частоту возникновения изменения функции почек и побочных эффектов терапии. РЕЗУЛЬТАТЫ В контрольной группе длительность вмешательства была меньше и составила 70 [59; 82] мин, в основной группе — 83 [65; 94] мин (p=0,05). Не выявили достоверной разницы в количестве болюсов (32 [22; 38] и 23 [15; 36]; p=0,085) и интенсивности болевого синдрома через 2 и 12 ч после начала терапии (5 [4; 6] и 3 [2; 4] и 5 [4; 6] и 2 [2; 3] баллов) между контрольной и основной группами. Через 24 ч после начала терапии интенсивность болевого синдрома в группах различалась: 30 [2; 3] мм в группе контроля, 20 [2; 3] мм в основной группе (p=0,05). Нефротоксического эффекта при применении Неодолпассе отмечено не было. Частота возникновения таких побочных явлений, как тошнота, рвота, кожный зуд, в группах была сопоставимой, что объяснимо введением морфина. ЗАКЛЮЧЕНИЕ 1. Применение комбинации орфенадрин 30 мг + диклофенак 75 мг после первичного протезирования тазобедренного сустава улучшает качество послеоперационного обезболивания по субъективной оценке пациентов. 2. Использование комбинации орфенадрин 30 мг + диклофенак 75 мг не привело к развитию побочных эффектов и осложнений.

1 January 2022 in Russian Journal of Anesthesiology and Reanimatology
Verified
Journal Article
Closed access
MBM.V. Bychinin
M.V. Bychinin
TKT.V. Klypa
T.V. Klypa
Irina MandelIrina Mandel
Irina Mandel
PAPavel Avdonin
Pavel Avdonin
DKD.I. Korshunov
D.I. Korshunov